Clozapine: Uses, Dosage & Side Effects
Atypical antipsychotic for treatment-resistant schizophrenia — the gold standard when other antipsychotics fail
Clozapine is a unique atypical antipsychotic medication considered the gold standard for treatment-resistant schizophrenia. It is the only antipsychotic with proven superiority when other medications have failed, and the only one approved for reducing the risk of recurrent suicidal behavior. Clozapine requires mandatory blood monitoring due to the risk of a serious decrease in white blood cells (agranulocytosis). Despite its side effect profile, clozapine remains irreplaceable for patients who do not respond to other treatments.
Quick Facts
Key Takeaways
- Clozapine is the only antipsychotic proven effective for treatment-resistant schizophrenia, with 30–60% of previously non-responding patients showing improvement.
- Mandatory blood monitoring is required — weekly for the first 18 weeks, then monthly — to detect potentially life-threatening neutropenia (agranulocytosis).
- It is the only antipsychotic approved by the FDA for reducing the risk of suicidal behavior in schizophrenia and schizoaffective disorder.
- Common side effects include drowsiness, weight gain, hypersalivation, constipation, and tachycardia — many improve over time with dose adjustment.
- Clozapine must never be stopped abruptly; doses should be tapered gradually over 1–2 weeks to prevent withdrawal symptoms and rebound psychosis.
What Is Clozapine and What Is It Used For?
Clozapine belongs to the class of medications known as atypical (second-generation) antipsychotics, specifically within the dibenzodiazepine subgroup. First synthesized in 1958 and introduced clinically in the 1970s, clozapine was temporarily withdrawn from the market in 1975 after cases of fatal agranulocytosis. It was reintroduced in 1990 with mandatory blood monitoring protocols and has since become indispensable in psychiatric practice.
The active ingredient, clozapine, exerts its therapeutic effects by blocking multiple neurotransmitter receptors in the brain, including dopamine (D1, D2, D3, D4), serotonin (5-HT2A, 5-HT2C), muscarinic, histaminergic, and adrenergic receptors. Unlike typical antipsychotics, clozapine has relatively weak dopamine D2 receptor binding, which is thought to contribute to its unique efficacy and lower risk of extrapyramidal side effects (movement disorders).
Approved Indications
Clozapine is specifically indicated for three conditions:
- Treatment-resistant schizophrenia: Defined as inadequate response to at least two different antipsychotic medications given at adequate doses for adequate duration (typically 6–8 weeks each), including at least one atypical antipsychotic. This is the primary indication, and clozapine remains the only medication with proven superior efficacy in this population.
- Psychotic disturbances in Parkinson’s disease: When standard treatments have failed, clozapine can be used at very low doses (typically 12.5–50 mg/day) to manage psychotic symptoms without significantly worsening motor function, due to its relatively low D2 receptor affinity.
- Reduction of suicidal risk: Clozapine is FDA-approved for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder, based on the landmark InterSePT (International Suicide Prevention Trial) study.
Beyond these approved indications, clozapine has demonstrated benefits in clinical practice for severe aggression in schizophrenia, treatment-resistant schizoaffective disorder, and tardive dyskinesia caused by other antipsychotics. However, these represent off-label uses and should be carefully considered by a specialist psychiatrist.
Despite decades of pharmaceutical development, no other antipsychotic has matched clozapine’s efficacy in treatment-resistant schizophrenia. Meta-analyses consistently confirm its superiority, and international guidelines (NICE, APA, WFSBP) unanimously recommend it as the treatment of choice when other antipsychotics fail. It is listed on the WHO Model List of Essential Medicines.
What Should You Know Before Taking Clozapine?
Clozapine is a powerful medication that requires careful medical evaluation before treatment begins. Your prescribing psychiatrist will conduct a thorough assessment of your medical history, current medications, and baseline blood tests. Understanding the contraindications and precautions is essential for safe treatment.
Contraindications
Do not take clozapine if any of the following apply to you:
- Allergy (hypersensitivity) to clozapine or any of the inactive ingredients in the tablets
- Inability to undergo regular blood monitoring as required by the clozapine monitoring program
- History of clozapine-induced neutropenia or agranulocytosis (severely low white blood cell count)
- History of drug-induced agranulocytosis from other medications (except chemotherapy-related)
- Impaired bone marrow function or blood disorders affecting white blood cell production
- Current use of medications known to suppress bone marrow function (e.g., carbamazepine, chloramphenicol)
- Uncontrolled epilepsy (clozapine lowers the seizure threshold)
- Acute psychotic states caused by alcohol or drug intoxication
- Severe kidney disease or severe liver disease (including active hepatitis with jaundice)
- Myocarditis (inflammation of the heart muscle) or other serious heart disease
- Paralytic ileus (severe bowel obstruction) or severe constipation
- Current treatment with long-acting depot antipsychotic injections
- Circulatory collapse or severe hypotension
- Reduced consciousness, coma, or severe CNS depression
Clozapine can cause a potentially life-threatening reduction in white blood cells called agranulocytosis, occurring in approximately 0.8% of patients. Without adequate white blood cells, your body cannot fight infections. You must commit to regular blood tests before starting and throughout treatment. Your prescriber will not be able to issue clozapine prescriptions without confirmed blood test results.
Warnings and Precautions
Before starting treatment, inform your doctor if you have or have ever had:
- Blood clots (deep vein thrombosis, pulmonary embolism) or a family history of thrombosis
- Diabetes mellitus or risk factors for diabetes — clozapine can cause significant increases in blood sugar
- Heart disease, heart rhythm disturbances, or QT prolongation (personal or family history)
- Elevated cholesterol or triglycerides — clozapine frequently affects lipid metabolism
- Glaucoma (increased pressure in the eye)
- Prostate problems or difficulty urinating
- Chronic constipation or use of medications that cause constipation
- Controlled epilepsy or history of seizures
- Liver or kidney disease
- History of bowel disease or previous abdominal surgery
- Increased stroke risk (high blood pressure, cardiovascular disease)
- Signs of infection: fever, sore throat, flu-like symptoms — may indicate low white blood cell count
- Rapid heartbeat, palpitations, chest pain, or unexplained fatigue — may indicate myocarditis
- High fever with muscle stiffness — may indicate neuroleptic malignant syndrome (NMS)
- Severe constipation, abdominal pain, bloating — may indicate bowel complications
- Nausea, vomiting, loss of appetite, jaundice — may indicate liver problems
Blood Monitoring Schedule
The blood monitoring protocol for clozapine follows a strict schedule designed to detect neutropenia before it becomes dangerous:
| Treatment Phase | Frequency | Duration |
|---|---|---|
| Before starting | Baseline blood test (within 10 days) | Once |
| Weeks 1–18 | Weekly | 18 weeks |
| Weeks 19–52 | Every 2 weeks (minimum) | Up to 1 year |
| After 1 year | Monthly (minimum) | Ongoing |
| After discontinuation | Weekly | 4 weeks after last dose |
If blood tests reveal a significant drop in your absolute neutrophil count (ANC), clozapine must be stopped immediately. In most cases, white blood cell counts return to normal within 2–4 weeks after discontinuation. The monitoring program also includes additional checks for metabolic parameters, liver function, and cardiac health at your doctor’s discretion.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor before starting clozapine. Key considerations include:
- Pregnancy: Clozapine should only be used during pregnancy when the potential benefits clearly outweigh the risks. Newborns exposed to antipsychotics during the third trimester may experience withdrawal symptoms including tremor, muscle stiffness, sleepiness, agitation, breathing difficulties, and feeding problems. If you become pregnant while taking clozapine, contact your doctor immediately — do not stop the medication on your own.
- Breastfeeding: Clozapine passes into breast milk and can affect the infant. Breastfeeding is not recommended during clozapine treatment.
- Fertility: Some women with schizophrenia taking other antipsychotics may experience irregular or absent menstrual periods. When switching to clozapine, normal menstruation may return, so effective contraception should be used.
Children and Adolescents
Clozapine is generally not recommended for patients under 16 years of age due to insufficient data in this age group. However, in specialized pediatric psychiatric settings, it may be considered for treatment-resistant schizophrenia in adolescents under close monitoring.
Elderly Patients (60 Years and Older)
Older adults are more susceptible to certain side effects of clozapine, including orthostatic hypotension (dizziness when standing), sedation, tachycardia, urinary retention, and constipation. Treatment in elderly patients typically begins at lower doses with slower titration. Patients with dementia-related psychosis treated with antipsychotics have an increased risk of mortality; clozapine should be used with particular caution in this population.
Driving and Operating Machinery
Clozapine can cause significant drowsiness, sedation, and seizures, especially during the initial dose titration period. Do not drive or operate machinery until you know how the medication affects you. Your ability to perform these activities safely should be assessed on an individual basis in consultation with your doctor.
How Does Clozapine Interact with Other Drugs?
Clozapine is primarily metabolized by the cytochrome P450 enzymes CYP1A2 and, to a lesser extent, CYP3A4 and CYP2D6. This means that medications that inhibit or induce these enzymes can significantly alter clozapine blood levels, potentially causing toxicity or loss of efficacy. Additionally, combining clozapine with drugs that have similar pharmacological effects can amplify side effects.
Major Interactions (Avoid Combination)
| Drug / Class | Interaction | Risk |
|---|---|---|
| Carbamazepine | Bone marrow suppression + CYP1A2 induction | Increased agranulocytosis risk; reduced clozapine levels |
| Chloramphenicol | Bone marrow suppression | Additive risk of agranulocytosis |
| Sulfonamides (e.g., co-trimoxazole) | Bone marrow suppression | Additive risk of neutropenia |
| Pyrazolone analgesics (phenylbutazone) | Bone marrow suppression | Additive risk of agranulocytosis |
| Penicillamine | Bone marrow suppression | Increased risk of neutropenia |
| Cytotoxic agents (chemotherapy) | Bone marrow suppression | Severely increased agranulocytosis risk |
| Depot antipsychotics | Cannot be rapidly discontinued if neutropenia occurs | Inability to stop medication quickly in emergency |
Clinically Significant Interactions (Use with Caution)
| Drug / Substance | Effect on Clozapine | Clinical Action |
|---|---|---|
| Fluvoxamine | Strong CYP1A2 inhibitor; can increase clozapine levels 5–10 fold | Avoid or reduce clozapine dose significantly |
| Ciprofloxacin | CYP1A2 inhibitor; can double clozapine levels | Reduce clozapine dose; monitor levels |
| Tobacco smoking | CYP1A2 inducer; smoking cessation increases clozapine levels up to 50% | Adjust dose when starting/stopping smoking |
| Caffeine | CYP1A2 substrate competition; can increase clozapine levels | Maintain consistent caffeine intake |
| Rifampicin | CYP3A4 inducer; significantly reduces clozapine levels | May need clozapine dose increase |
| Phenytoin / Valproate | Enzyme inducers; may reduce clozapine levels | Monitor clozapine levels; adjust dose |
| Benzodiazepines | Additive CNS depression; rare reports of cardiac/respiratory arrest | Use with extreme caution; low doses |
| Lithium | Possible increased risk of NMS and seizures | Monitor closely; watch for NMS symptoms |
| SSRIs (fluoxetine, paroxetine, sertraline) | May modestly increase clozapine levels via CYP2D6 inhibition | Monitor for increased side effects |
| Erythromycin / Ketoconazole | CYP3A4 inhibitors; may increase clozapine levels | Monitor clozapine levels if co-prescribed |
| Hormonal contraceptives | May affect clozapine metabolism | Monitor for changes in efficacy/side effects |
Polycyclic aromatic hydrocarbons in tobacco smoke (not nicotine itself) strongly induce CYP1A2, which metabolizes clozapine. Smokers typically require 50% higher clozapine doses than non-smokers. If a patient suddenly stops smoking (e.g., during hospitalization), clozapine levels can rise rapidly and cause toxicity. Conversely, starting smoking can reduce clozapine levels below the therapeutic range. Nicotine replacement therapy (patches, gum) does not affect CYP1A2 and does not require dose adjustment.
Alcohol
Alcohol should be avoided during clozapine treatment. Alcohol enhances the sedative effects of clozapine and can worsen orthostatic hypotension (dizziness when standing), increasing the risk of falls. Alcohol also affects liver function and can interfere with clozapine metabolism.
What Is the Correct Dosage of Clozapine?
Clozapine dosing follows a strict slow-titration protocol to minimize the risk of serious side effects including severe hypotension, seizures, and excessive sedation. Your doctor will increase the dose gradually based on your response and tolerability. It is critical that you do not change your dose or stop taking the medication without consulting your doctor.
Adults — Schizophrenia
Starting Dose
Day 1: 12.5 mg (half a 25 mg tablet) once or twice. Day 2: 25 mg once or twice daily. The dose is then increased gradually by 25–50 mg per day until a target dose of approximately 300 mg/day is reached within 2–3 weeks, if tolerated.
Maintenance Dose
The effective dose varies widely between patients. Most patients respond to doses between 200–450 mg/day, typically divided into two or three doses, with the larger portion given at bedtime to manage sedation. Some patients may require up to 900 mg/day, though doses above 450 mg/day increase the risk of seizures and other side effects.
Therapeutic Drug Monitoring
Plasma clozapine levels can guide dosing. The generally accepted therapeutic range is 350–600 ng/mL (trough level, measured 12 hours after the last dose). Levels above 1,000 ng/mL are associated with increased toxicity risk.
Parkinson’s Disease Psychosis
Dosing Protocol
Treatment begins with 12.5 mg/day (half a 25 mg tablet), taken in the evening. Dose increases of 12.5 mg are made no more than twice weekly, up to a maximum of 50 mg/day. The effective dose is typically between 25 and 37.5 mg per day. Much lower doses are used compared to schizophrenia because elderly patients with Parkinson’s disease are more sensitive to both the therapeutic and adverse effects.
Elderly Patients
For patients aged 60 and older, treatment should start at the lowest possible dose (12.5 mg on day one) with slower titration than in younger adults. Elderly patients have a higher risk of orthostatic hypotension, falls, sedation, and anticholinergic effects. Lower maintenance doses are often sufficient.
Children and Adolescents
Clozapine is not recommended for patients under 16 years of age due to limited safety data. In exceptional cases, specialist pediatric psychiatrists may prescribe it for treatment-resistant early-onset schizophrenia with very careful monitoring.
Missed Dose
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose.
If you have not taken clozapine for more than 48 hours, do not restart at your previous dose. Contact your doctor immediately. The medication must be re-titrated from the starting dose (12.5 mg) because of the risk of severe hypotension, syncope, and cardiac complications. This applies regardless of your previous maintenance dose.
Overdose
If you take too much clozapine, seek emergency medical attention immediately. Symptoms of overdose may include:
- Severe drowsiness or loss of consciousness progressing to coma
- Confusion, hallucinations, agitation
- Seizures
- Rapid or irregular heartbeat
- Excessive salivation
- Low blood pressure and circulatory collapse
- Difficulty breathing or respiratory depression
- Blurred vision, dilated pupils
There is no specific antidote for clozapine overdose. Treatment is supportive and may include gastric lavage, activated charcoal, and monitoring in an intensive care setting.
Stopping Clozapine
Do not stop taking clozapine without your doctor’s guidance. Abrupt discontinuation can cause withdrawal symptoms including profuse sweating, headache, nausea, vomiting, and diarrhea. More seriously, sudden cessation can lead to rebound psychosis — a rapid worsening of psychiatric symptoms that may be more severe than the original condition.
When discontinuation is necessary, the dose should be reduced gradually in steps of 12.5 mg over 1–2 weeks under medical supervision. If rapid discontinuation is required for medical reasons (e.g., myocarditis, severe neutropenia), your doctor will monitor you closely for withdrawal effects and psychotic relapse.
What Are the Side Effects of Clozapine?
Like all medications, clozapine can cause side effects, though not everyone experiences them. Due to its broad receptor binding profile, clozapine affects multiple body systems. Understanding potential side effects helps you recognize them early and work with your doctor to manage them effectively. Many side effects are dose-dependent and most pronounced during initial dose titration.
Very Common (affects more than 1 in 10 patients)
- Drowsiness and sedation — most pronounced during initial titration; often improves over time
- Dizziness — related to orthostatic hypotension
- Tachycardia (rapid heartbeat) — common early in treatment; usually benign
- Constipation — can be severe; requires proactive management
- Hypersalivation (excessive saliva production) — especially during sleep; paradoxical given anticholinergic properties
Common (affects 1 to 10 in 100 patients)
- Weight gain — can be substantial (average 4–10 kg in first year); metabolic monitoring recommended
- Leukocytosis (increased white blood cells) and eosinophilia
- Blurred vision, headache, tremor
- Rigidity, restlessness, involuntary movements
- EKG changes, high blood pressure
- Nausea, vomiting, dry mouth, loss of appetite
- Elevated liver enzymes
- Urinary incontinence or retention
- Fatigue, fever, sweating, increased body temperature
- Speech difficulties (e.g., slurred speech)
- Syncope (fainting)
- Seizures
Uncommon (affects 1 to 10 in 1,000 patients)
- Agranulocytosis (severe neutropenia) — potentially life-threatening; detected through mandatory blood monitoring
- Neuroleptic malignant syndrome (NMS) — fever, muscle rigidity, altered consciousness; medical emergency
- Stuttering or other speech difficulties
- Orthostatic hypotension with falls
Rare to Very Rare (affects fewer than 1 in 1,000 patients)
- Myocarditis and cardiomyopathy — inflammation/disease of heart muscle; highest risk in first 2 months
- Pericarditis and pericardial effusion
- Pulmonary embolism, deep vein thrombosis
- Pancreatitis, hepatitis, liver failure
- Intestinal obstruction, paralytic ileus, megacolon
- Respiratory arrest or depression
- Diabetes mellitus (new onset)
- Severe dyslipidemia (very high triglycerides/cholesterol)
- Priapism (persistent painful erection)
- Sleep apnea
- Thrombocytopenia (low platelets)
- Rhabdomyolysis (muscle breakdown)
- DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
- Sudden cardiac death, cardiac arrest (very rare)
While constipation may seem minor, clozapine-associated constipation can progress to life-threatening complications including paralytic ileus, bowel obstruction, intestinal ischemia, and perforation. Studies suggest clozapine-related gastrointestinal complications may cause more deaths than agranulocytosis. Proactive bowel management with adequate fluid intake, dietary fiber, and laxatives when needed is essential throughout treatment.
Metabolic Side Effects
Clozapine is among the antipsychotics with the highest metabolic risk. Regular monitoring should include:
- Weight: Monthly for the first 6 months, then quarterly. Average weight gain is 4–10 kg in the first year.
- Blood glucose: Fasting glucose at baseline, at 12 weeks, then annually. New-onset diabetes occurs in approximately 10–15% of patients over several years.
- Lipid panel: At baseline, at 12 weeks, then annually. Significant increases in triglycerides and cholesterol are common.
- Blood pressure: Regular monitoring, especially during initial titration.
Cardiac Monitoring
Myocarditis (inflammation of the heart muscle) is a rare but serious complication that occurs most frequently within the first 2 months of treatment. Symptoms include tachycardia, chest pain, fatigue, and flu-like symptoms. Your doctor may perform an ECG before starting treatment and periodically during the first months. Any unexplained persistent tachycardia, chest pain, or signs of heart failure should be investigated immediately with cardiac biomarkers (troponin, CRP, BNP) and echocardiography.
How Should You Store Clozapine?
Proper storage of clozapine ensures the medication remains effective and safe throughout its shelf life. Follow these guidelines:
- Temperature: Store at room temperature (below 25°C / 77°F). No special temperature requirements beyond this.
- Moisture: Keep tablets in their original packaging to protect from moisture. Do not store in the bathroom.
- Light: Protect from direct sunlight and excessive light exposure.
- Children: Store out of sight and reach of children. Clozapine can be extremely dangerous if taken by someone for whom it was not prescribed, especially children.
- Expiration: Do not use the medication after the expiration date printed on the packaging. The expiration date refers to the last day of that month.
- Disposal: Do not dispose of unused medication in household waste or down the drain. Return unused or expired tablets to your pharmacy for safe disposal, in accordance with local regulations.
What Does Clozapine Contain?
Active Ingredient
Each tablet contains clozapine as the active substance. Available strengths are 25 mg, 100 mg, and 200 mg, though availability varies by manufacturer and country.
Inactive Ingredients (Excipients)
The inactive ingredients that make up the tablet formulation typically include:
- Lactose monohydrate
- Magnesium stearate
- Povidone
- Talc
- Corn starch (maize starch)
- Colloidal anhydrous silica (silicon dioxide)
- Pregelatinized starch
Clozapine tablets contain lactose monohydrate. If you have been diagnosed with lactose intolerance or a rare hereditary condition of galactose intolerance, consult your doctor before taking this medication.
Tablet Appearance
Clozapine 25 mg tablets are typically yellow, round, approximately 6 mm in diameter, with a score line on both sides. The tablets can be divided into two equal halves along the score line for dose flexibility. The 100 mg tablets are similar in appearance but larger (approximately 10 mm diameter). Specific appearance may vary between manufacturers.
Frequently Asked Questions About Clozapine
Medical References
All medical information on this page is based on peer-reviewed research, international clinical guidelines, and regulatory authority documents. The following sources were consulted:
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Clozapine is included as an essential medicine for psychiatric disorders. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Clozapine Summary of Product Characteristics (SmPC). European public assessment reports. Available at: www.ema.europa.eu
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management [CG178]. London: NICE; 2014 (updated 2024).
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-3
- Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91. doi:10.1001/archpsyc.60.1.82
- Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–392. doi:10.1192/bjp.bp.115.177261
- De Berardis D, Rapini G, Carano A, et al. Clozapine-related neutropenia: prevalence, pathophysiology and management. CNS Drugs. 2022;36(10):1035–1052.
- Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study. CNS Drugs. 2017;31(8):699–709.
- U.S. Food and Drug Administration (FDA). Clozapine REMS (Risk Evaluation and Mitigation Strategy). Updated 2024. Available at: www.fda.gov
- British National Formulary (BNF). Clozapine monograph. London: BMJ Group and Pharmaceutical Press; 2025. Available at: bnf.nice.org.uk
Medical Editorial Team
This article has been written and reviewed by our medical editorial team according to international guidelines and evidence-based medicine principles.
📋 Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
🔎 Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
🔄 Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
✏️ Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in psychiatry, psychopharmacology, and internal medicine.